Results 51 to 60 of about 1,519,611 (347)

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer

Frontiers in Oncology, 2022
ObjectiveWe conducted a phase 2 trial to compare the safety and efficacy of intravenous paclitaxel or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 in untreated advanced gastric cancer.MethodsParticipants with untreated advanced gastric cancer ...
Shen Zhao, Shen Zhao, Liyu Su, Yigui Chen, Xiaofeng Li, Peicheng Lin, Wujin Chen, Wenzheng Fang, Jinfeng Zhu, Hui Li, Liping Ren, Jie Liu, Yanni Hong, Shaowei Lin, Nanfeng Fan, Rongbo Lin, Rongbo Lin   +16 more
doaj   +1 more source

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

American Journal of Psychiatry, 2016
OBJECTIVE Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression.
Jaskaran Singh, M. Fedgchin, E. Daly, P. de Boer, K. Cooper, P. Lim, C. Pinter, J. Murrough, G. Sanacora, R. Shelton, B. Kurian, A. Winokur, M. Fava, H. Manji, W. Drevets, L. van Nueten   +15 more
semanticscholar   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Inadvertent intravenous injection of carboprost in a COVID-19-positive patient: A case report

Journal of Obstetric Anaesthesia and Critical Care, 2022
We present a case report of an inadvertent administration of intravenous carboprost in a COVID-19-positive parturient who was taken up for an emergency caesarean section for meconi um-stained liquor.
Nazia Nazir, Deepti Chopra
doaj   +1 more source

Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.

New England Journal of Medicine, 2016
BACKGROUND Thrombolytic therapy for acute ischemic stroke with a lower-than-standard dose of intravenous alteplase may improve recovery along with a reduced risk of intracerebral hemorrhage.
C. Anderson, T. Robinson, R. Lindley, H. Arima, P. Lavados, Tsong-Hai Lee, J. Broderick, Xiaoying Chen, Guofang Chen, V. Sharma, J. S. Kim, N. H. Thang, Yongjun Cao, M. Parsons, C. Levi, Yining Huang, V. Olavarría, A. Demchuk, P. Bath, G. Donnan, S. Martins, O. Pontes-Neto, F. Silva, S. Ricci, C. Roffe, J. Pandian, L. Billot, M. Woodward, Qiang Li, Xia Wang, Jiguang Wang, J. Chalmers   +31 more
semanticscholar   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Increasing Superoxide Production and the Labile Iron Pool in Tumor Cells May Sensitize Them to Extracellular Ascorbate

Frontiers in Oncology, 2014
Low millimolar concencentrations of ascorbate are capable of inflicting lethal damage on a high proportion of cancer cells lines, yet leave non-transformed cell lines unscathed; extracellular generation of hydrogen peroxide, reflecting reduction of ...
Mark Frederick Mccarty, Francisco eContreras   +1 more
doaj   +1 more source

Intravenous Catheters

Veterinary Clinics of North America: Small Animal Practice, 1982
Veterinary Clinics of North America: Small Animal Practice 12 (1982) 533-543. doi:10.1016/S0195-5616(82)50060-5 ; Received by publisher: 0000-01-01 ; Harvest Date: 2016-01-04 12:21:48 ; DOI:10.1016/S0195-5616(82)50060-5 ; Page Range: 533 ...
Nurse Anesthetist, Veterinary Medical Teaching Hospital, University of Florida College of Veterinary Medicine, Gainesville, Florida ( host institution ), Spencer, Karen R. ( author )   +1 more
openaire   +3 more sources

Development of 4T1 breast cancer mouse model system for preclinical carbonic anhydrase IX studies

FEBS Open Bio, EarlyView.
Carbonic anhydrase IX (CAIX) is a well‐recognised therapeutic target and prognostic biomarker in cancer. We developed and characterised a robust murine breast cancer model system that is suitable for CAIX studies in vitro and in vivo—it comprises both CAIX‐positive and CAIX‐negative controls and provides a solid platform for the comprehensive ...
Zane Kalniņa, Ilva Liekniņa, Svetlana Koteloviča, Ramona Petrovska, Gediminas Žvinys, Agne Petrosiute, Asta Zubrienė, Matīss Toms Laugalis, Vendija Skeltona, Juris Jansons, Madara Kreishmane, Edita Čapkauskaitė, Daumantas Matulis, Kaspars Tārs   +13 more
wiley   +1 more source